Piramal Pharma Limited — PPTs, 14-05-2025: Investor Presentation

1. Financial Highlights:

Piramal Pharma’s Q4 revenue grew 8% YoY to ₹2,754 Cr, with FY25 revenue up 12% at ₹9,151 Cr. The CDMO segment led growth, rising 15% YoY to ₹5,447 Cr. EBITDA increased 8% in Q4 to ₹603 Cr and 15% for FY25 to ₹1,580 Cr, with margins steady at 22% in Q4 and 17% annually. Net profit before exceptional items rose 16% in Q4 and 13% in FY25, while net profit after exceptional items surged 52% in Q4 and over 4x in FY25, reflecting operational improvements and cost discipline. Net debt declined to ₹4,199 Cr, improving net debt/EBITDA to 2.7x from 5.6x two years ago.

2. Strategic Initiatives & Growth Drivers:

The focus is on innovation-driven CDMO work, now 54% of revenue, powered by 50%+ YoY growth in on-patent manufacturing ($179mn). Differentiated CDMO offerings grew 28%, aided by cost optimization. In the Consumer Healthcare (CHG) segment, capacity expansion in India completed on time to tap a $400mn Sevoflurane opportunity internationally. India Consumer Healthcare crossed ₹1,000 Cr with 20% growth in core brands, 21% e-commerce sales, and 21 new product launches backed by increased marketing.

3. Business Developments:

Received approvals for Neoatricon®, a pre-diluted pediatric dopamine formulation, entering new EU and UK markets via partner BrePco Pharma. The CDMO pipeline strengthened with 18 on-patent molecules and 15 globally distributed manufacturing sites. ICH expanded distribution across 20+ e-commerce platforms and direct channels. CHG renewed key GPO contracts, consolidating leadership in inhalation anesthetics and intrathecal therapies.

4. Market Position & Competitive Advantage:

Dominates US markets with 44% share in Sevoflurane and 75% in Baclofen. Achieved zero major regulatory audit findings since 2011 over 36 inspections, highlighting exceptional quality. Over 500 CDMO customers globally, with 85% revenue from regulated markets and strong client relationships averaging 7+ years. Integrated global footprint with 17 development and manufacturing facilities enhances scale and cross-selling capabilities.

5. Investor Implications:

Strong growth in high-margin on-patent CDMO and ICH brands supports positive growth potential. Capacity expansions and new product launches enable market share gains and diversification. Improved leverage with net debt/EBITDA down significantly is credit-positive. Execution of capacity ramp-up, margin recovery in CHG, and progress toward FY2030 targets ($2bn revenue, 25% EBITDA margin) are key factors to watch.